Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile.

Interestingly, in non‐ICU patients, although the primary outcome did not reach statistical significance, the HR was 0.45 [0.09–2.17], suggesting a trend toward a beneficial effect of the JAK–CNI combination, which might have reached significance in a larger cohort.

also in 111,027 other papers